In vitro activity of β-lactams in combination with avibactam against multidrug-resistant Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Achromobacter xylosoxidans isolates from patients with cystic fibrosis

Clinical experience with ceftazidime/avibactam for treatment of antibiotic-resistant organisms other than Klebsiella pneumoniae

(2018) Barbara A. Santevecchi et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

ECFS best practice guidelines: the 2018 revision

(2018) Carlo Castellani et al.   Journal of Cystic Fibrosis

Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial

(2018) Antoni Torres et al.   LANCET INFECTIOUS DISEASES

Relevance of multidrug-resistant Pseudomonas aeruginosa infections in cystic fibrosis

(2017) S. Stefani et al.   INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY

Prevalence and Outcomes of Achromobacter Species Infections in Adults with Cystic Fibrosis: a North American Cohort Study

(2017) B. D. Edwards et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Successful Treatment of Bloodstream Infection Due to Metallo-β-Lactamase-Producing Stenotrophomonas maltophilia in a Renal Transplant Patient

(2016) Maria F. Mojica et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Cystic fibrosis

(2016) J Stuart Elborn   LANCET

Future trends in cystic fibrosis demography in 34 European countries

(2015) Pierre-Régis Burgel et al.   EUROPEAN RESPIRATORY JOURNAL

Avibactam confers susceptibility to a large proportion of ceftazidime-resistantPseudomonas aeruginosaisolates recovered from cystic fibrosis patients

(2015) Hussein Chalhoub et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Diversity of  -lactam resistance mechanisms in cystic fibrosis isolates of Pseudomonas aeruginosa: a French multicentre study

(2013) C. Llanes et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Chronic Stenotrophomonas maltophilia infection and mortality or lung transplantation in cystic fibrosis patients

(2013) Valerie Waters et al.   Journal of Cystic Fibrosis

Avibactam is a covalent, reversible, non- -lactam  -lactamase inhibitor

(2012) D. E. Ehmann et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

First Description of an RND-Type Multidrug Efflux Pump in Achromobacter xylosoxidans, AxyABM

(2011) Julien Bador et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Efflux Pumps, OprD Porin, AmpC  -Lactamase, and Multiresistance in Pseudomonas aeruginosa Isolates from Cystic Fibrosis Patients

(2010) M. Tomas et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters

(2010) S. Mushtaq et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Cystic Fibrosis Pulmonary Guidelines

(2009) Patrick A. Flume et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE